Last reviewed 2026-04-20 · How we verify

Senl-h19 CAR-T

Hebei Senlang Biotechnology Inc., Ltd. · Phase 1 active Biologic Quality 3/100

Senl-h19 CAR-T is a Biologic drug developed by Hebei Senlang Biotechnology Inc., Ltd.. It is currently in Phase 1 development. Also known as: CD19 CAR-T.

At a glance

Generic name	Senl-h19 CAR-T
Also known as	CD19 CAR-T
Sponsor	Hebei Senlang Biotechnology Inc., Ltd.
Modality	Biologic
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Senl-h19 CAR-T Cell Injection in the Treatment of Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (NA)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Senl-h19 CAR-T CI brief — competitive landscape report
Senl-h19 CAR-T updates RSS · CI watch RSS
Hebei Senlang Biotechnology Inc., Ltd. portfolio CI

Frequently asked questions about Senl-h19 CAR-T

What is Senl-h19 CAR-T?

Senl-h19 CAR-T is a Biologic drug developed by Hebei Senlang Biotechnology Inc., Ltd..

Who makes Senl-h19 CAR-T?

Senl-h19 CAR-T is developed by Hebei Senlang Biotechnology Inc., Ltd. (see full Hebei Senlang Biotechnology Inc., Ltd. pipeline at /company/hebei-senlang-biotechnology-inc-ltd).

Is Senl-h19 CAR-T also known as anything else?

Senl-h19 CAR-T is also known as CD19 CAR-T.

What development phase is Senl-h19 CAR-T in?

Senl-h19 CAR-T is in Phase 1.

Manufacturer: Hebei Senlang Biotechnology Inc., Ltd. — full pipeline
Also known as: CD19 CAR-T
Compare: Senl-h19 CAR-T vs similar drugs
Pricing: Senl-h19 CAR-T cost, discount & access